-
公开(公告)号：KR1020110133223A
公开(公告)日：2011-12-12
申请号：KR1020100052835
申请日：2010-06-04
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12N9/00 , C12Q1/26 , C12Q1/6844 , C12Q2600/172
Abstract: PURPOSE: A method for predicting DPD(Dihydropyrimidine dehydrogenase) is provided to analyze genetic polymorphism of DPD and to develop a drug metabolized by DPD. CONSTITUTION: A method for analysis of Korean DPD gene haplotype comprises: a step of obtaining exon 13 and intron 13 encoding DPD from genome DNA to determine each base sequence; a step of detecting SNP in the determined each base sequence; and a step of identifying haplotype selected among Hap1 to Hap3 using the detected SNP. A method for predicting Korean DPD comprises: a step of confirming a DPD gene of a person who is tested, among Hap1 to Hap3; and a step of predicting DPD activity using the confirmed haplotype information.
Abstract translation: 目的：提供一种预测DPD（二氢嘧啶脱氢酶）的方法，用于分析DPD的遗传多态性并开发DPD代谢的药物。 构成：分析韩国DPD基因单体型的方法包括：从基因组DNA获得编码DPD的外显子13和内含子13以确定每个碱基序列的步骤; 检测确定的每个碱基序列中的SNP的步骤; 以及使用检测到的SNP鉴定从Hap1至Hap3中选择的单元型的步骤。 用于预测韩国DPD的方法包括：在Hap1至Hap3中确认被测试人的DPD基因的步骤; 以及使用确认的单元型信息来预测DPD活性的步骤。
-
公开(公告)号：KR1020130102777A
公开(公告)日：2013-09-23
申请号：KR1020120023879
申请日：2012-03-08
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/15 , G01N2800/52
Abstract: PURPOSE: A method for predicting drug response to omeprazole using the genotype of cytochrome p450 2C19 (CYP2C19) gene is provided to analyze the genotype of CYP2C19 gene for predicting drug response to omeprazole and to present a proposal on drug approvals in consideration of Korean pharmacogenomics. CONSTITUTION: A method for analyzing the genotype of CYP2C19 gene for predicting drug response to omeprazole comprises the steps of: acquiring exon 4 and exon 5 of a gene encoding CYP2C19 from genomic DNA and determining each base sequence; detecting single nucleotide polymorphisms (SNPs) of each base sequence, wherein 39th base (G) of sequence number 1 (exon 5) is substituted with A (CYP2C19*2) and 155th base (G) of sequence number 2 (exon 4) is substituted with A (CYP2C19*3); and determining if the genotype of CYP2C19 belongs to extensive metabolizer (EM) group, intermediate metabolizer (IM) group, or poor metabolizer (PM) group using the detected SNP. A method for predicting drug response to omeprazole by each CYP2C19 genotype comprises the steps of: orally administering 20-80 mg of omeprazole to each of the EM, IM, and PM groups; and comparing the area under the concentration-time curve (AUC) by each genotype and computing a dosage of omeprazole by each genotype. [Reference numerals] (AA) Omeprazole (ng/mL); (BB) Elapse time after injecting (hr)
Abstract translation: 目的：提供使用细胞色素p450 2C19（CYP2C19）基因的基因型预测奥美拉唑药物反应的方法，以分析CYP2C19基因的基因型，以预测对奥美拉唑的药物反应，并提出考虑韩国药物基因组学的药物批准建议。 构成：分析CYP2C19基因基因型预测奥美拉唑药物应答的方法，包括以下步骤：从基因组DNA中获得编码CYP2C19基因的外显子4和外显子5，并确定每个碱基序列; 检测每个碱基序列的单核苷酸多态性（SNP），其中序列号1（外显子5）的第39位碱基（G）被序列号2（外显子4）的A（CYP2C19 * 2）和第155位碱基（G）取代为 用A（CYP2C19 * 3）取代; 并使用检测到的SNP确定CYP2C19的基因型是否属于广泛代谢（EM）组，中间代谢者（IM）组或不良代谢者（PM）组。 用于预测每种CYP2C19基因型对奥美拉唑的药物反应的方法包括以下步骤：向每个EM，IM和PM组口服20-80mg奥美拉唑; 并比较各基因型浓度 - 时间曲线下面积（AUC），并计算每种基因型的奥美拉唑剂量。 （AA）奥美拉唑（ng / mL）; （BB）注射后经过时间（小时）
-
公开(公告)号：KR1020130093920A
公开(公告)日：2013-08-23
申请号：KR1020120015167
申请日：2012-02-15
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
Abstract: PURPOSE: A method of analyzing a CYP2C19 genotype for predicting the effect of lansoprazole is provided to supply a haplotype as a drug-metabolizing enzyme activity index of CYP2C19 engaging in a lansoprazole metabolism and be used as an index about the evaluation of medical supplies metabolized by the CYP2C19 and a cross linkage test by grasping the pharmacokinetics characteristic of equivalent drugs. CONSTITUTION: A method of predicting the lansoprazole metabolic activation of a CYP2C19 protein comprises: a step of determining the each base sequence of the promoter of a gene ciphering cytochrome P450 2C19 (CYP2C19) from genomic DNA, exon 4, exon 5, intron 5 and intron 7; a step of detecting the presence of single nucleotide polymorphism (SNP) in the determined each base sequence; a step of identifying the CYP2C19 gene of experimentee with one among haplotype H1-H3 by using the detected SNP; a step of determining whether the identified haplotype belongs to a haplotype combination group consisting of extensive metabolizer (EM), hetero extensive metabolizer (hetero EM) and poor metabolizer (PM) by assembling the identified haplotype with base pairs; and a step of predicting the lansoprazole metabolic activation of the CYP2C19 protein by using the confirmed haplotype combination group. The lansoprazole metabolic activity is the highest when the haplotype combination group belongs to the EM and is lowest when the haplotype combination group belongs to the PM.
Abstract translation: 目的：提供一种分析CYP2C19基因型以预测兰索拉唑效应的方法，以提供单倍型作为参与兰索拉唑代谢的CYP2C19的药物代谢酶活性指数，并用作关于由 CYP2C19和通过抓取等效药物的药代动力学特征进行交联试验。 组成：预测CYP2C19蛋白的兰索拉新陈代谢活化的方法包括：从基因组DNA，外显子4，外显子5，内含子5中确定加密细胞色素P450 2C19（CYP2C19）基因的启动子的每个碱基序列的步骤，以及 内含子7 检测确定的每个碱基序列中单核苷酸多态性（SNP）的存在的步骤; 通过使用检测到的SNP，在单倍型H1-H3中鉴定实验者的CYP2C19基因的步骤; 通过将识别的单倍型与碱基对组合来确定所识别的单倍型是否属于由广泛代谢（EM），杂广泛代谢（异质EM）和不良代谢者（PM）组成的单倍型组合组的步骤; 以及通过使用确认的单倍型组合组预测CYP2C19蛋白的兰索拉唑代谢活化的步骤。 当单倍型组合属于EM时，兰索拉唑代谢活性最高，单倍型组合属于PM时，代谢活性最低。
-
公开(公告)号：KR101277793B1
公开(公告)日：2013-06-25
申请号：KR1020100092900
申请日：2010-09-24
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 한국인을 대상으로 UGT1A1를 암호화하는 유전자의 프로모터 부위내에 위치한 단일염기다형성(SNP)로부터 특정 일배체형(Haplotype)을 결정하였으며, 이 특정 일배체형(Haplotype)을 분석할 수 있는 상기 유전자 프로모터의 증폭용 프라이머를 포함하는 UGT1A1 유전자 프로모터의 일배체형의 분석키트 및 이를 이용한 분석방법에 관한 것이다. 본 발명에 따른 분석키트 및 분석 방법을 이용하면, UGT1A1 유전자의 발현 정도를 예측할 수 있으며, 또한, 이에 따라 개인간 유전형의 차이에 따른 맞춤의약을 포함하여 UGT1A1에 의하여 대사되는 약물의 개발에 널리 활용할 수 있다.
-
公开(公告)号：KR101609725B1
公开(公告)日：2016-04-11
申请号：KR1020130102117
申请日：2013-08-28
Applicant: 대한민국 (식품의약품안전처장)
IPC: G06Q50/22
Abstract: 유전형진단결과를이용한개인별처방방법및 장치가개시되어있다. 개인맞춤형약물정보유도방법은약물유전형검사결과를기반으로개인맞춤약물정보를생성하는단계와상기개인맞춤약물정보를전송하는단계를포함할수 잇되,상기약물유전형검사결과는개인의약물대사에영향을끼칠수 있는유전자정보에대한검사를수행한결과일수 있다. 따라서, 개인별유전자정보에기반하여약물을투여할수 있어약물에의한부작용을방지할수 있다.
-
Patent Agency Ranking
公开(公告)号：KR1020140048482A
公开(公告)日：2014-04-24
申请号：KR1020120114378
申请日：2012-10-15
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/156
Abstract: The present invention relates to a method for predicting a drug reaction of tramadol using the genotype of CYP2D6 gene and, more specifically, to a method for predicting metabolic activity of the CYP2D6 enzyme by analyzing single nucleotide polymorphism (SNP) of CYP2D6 gene of Korean people using a primer capable of analyzing SNP and using the analyzed results. Further, the present invention relates to a method for predicting a drug reaction of tramadol by effectively measuring the blood drug concentration of tramadol according to the genotype of CYP2D6 gene. The method of the present invention is useful in selecting a safe drug treatment method and developing and evaluating the personalized drug therapy by predicting a drug reaction for a patient when tramadol is alone administered or co-administered with another drug, through determination of the type of CYP2D6 of the patient. [Reference numerals] (AA) 2.0 times
Abstract translation: 本发明涉及使用CYP2D6基因的基因型预测曲马多的药物反应的方法，更具体地，涉及通过分析韩国人CYP2D6基因的单核苷酸多态性（SNP）来预测CYP2D6酶的代谢活性的方法 使用能够分析SNP并使用分析结果的引物。 此外，本发明涉及一种通过根据CYP2D6基因的基因型有效测定曲马多的药物浓度来预测曲马多的药物反应的方法。 本发明的方法可用于选择安全药物治疗方法，并且通过预测单独施用曲马多或与另一种药物共同施用的患者的药物反应来开发和评估个性化药物治疗，通过确定 患者的CYP2D6。 （标号）（AA）<1.4倍; （BB）<2.0倍; （CC）> 2.0倍
-
公开(公告)号：KR1020110131630A
公开(公告)日：2011-12-07
申请号：KR1020100051165
申请日：2010-05-31
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6865 , C12Q2600/156 , C12Q2600/172
Abstract: PURPOSE: A haplotype analysis kit of NAT2 gene promoter and an analysis method using the same are provided to analyze genetic polymorphism of NAT2 and to develop a drug. CONSTITUTION: A method for analyzing haplotype of human NAT2 gene comprises: a step of performing PCR of genome DNA of a test person using a primer set for amplifying the human NAT2 gene promoter or fragment of the fragment; a step of analyzing base sequence of DNA product prepared by PCR; a step of determining SNP presence of -10818 T>C(2942th base of sequence number 8), -10065 A>G(3695th base of sequence number 8), -9905 T>C(3855th base of sequence number 8), -9601 A>G(4159th base of sequence number 8), -9246 G>C(4514th base of sequence number 8), or -8853 A>G(4907th base of sequence number 8).
Abstract translation: 目的：提供NAT2基因启动子的单倍型分析试剂盒及其分析方法，分析NAT2的遗传多态性，开发药物。 构成：用于分析人类NAT2基因单倍型的方法包括：使用引物组进行测试人基因组DNA的PCR扩增步骤，以扩增人类NAT2基因启动子或片段片段; 分析通过PCR制备的DNA产物碱基序列的步骤; 确定天然存在的步骤（序列号8的第2942个碱基），-10065A> G（序列号8的第3695位），-9905T> C（序列号8的第3855位）的SNP存在的步骤， （序列号815的第4159位），-9246G> C（序列号845的第4514位）或-8853A> G（序列号890的第497位）。
-
公开(公告)号：KR101035574B1
公开(公告)日：2011-05-23
申请号：KR1020090030892
申请日：2009-04-09
Applicant: 대한민국 (식품의약품안전처장)
IPC: G01N33/15 , G01N33/493
Abstract: 본 발명은 제 2형 당뇨병 치료제 후보약물을 제 2형 당뇨병을 수반하는 실험동물에 투여하고, 뇨에 포함된 특정 대사체의 농도를 측정하는 단계를 포함하는, 제 2형 당뇨병 치료효과를 판정하는 방법에 관한 것이다. 본 발명의 제 2형 당뇨병 치료효과를 판정하는 방법은, (ⅰ) 제 2형 당뇨병 치료제 후보약물을 제 2형 당뇨병을 수반하는 실험동물에 투여하고, 이로부터 뇨를 수집하여 뇨에 포함된 혈당수준 강하효과와 관련된 대사체의 농도를 측정하는 단계; 및, (ⅱ) 상기 뇨에 포함된 대사체의 농도를 약물을 주사하지 않은 대조군의 뇨에 포함된 대사체의 농도와 비교하여, 상기 후보약물이 제 2형 당뇨병 치료효과가 있는지의 여부를 판단하는 단계를 포함한다. 본 발명의 방법을 이용하면, 신약개발 단계에 있어서 제 2형 당뇨병 치료제 후보약물이 제 2형 당뇨병의 치료효과를 나타내는 지의 여부를 간편하게 판단할 수 있으므로, 제 2형 당뇨병의 치료제를 보다 효과적으로 개발할 수 있을 것이다.
제 2형 당뇨병 치료제, 후보약물, 뇨, 대사체-
公开(公告)号：KR1020100112396A
公开(公告)日：2010-10-19
申请号：KR1020090030892
申请日：2009-04-09
Applicant: 대한민국 (식품의약품안전처장)
IPC: G01N33/15 , G01N33/493
Abstract: PURPOSE: A method for determining an effect for type 2 diabetes is provided to simply know treatment effect of therapeutic candidate drug for type 2 diabetes. CONSTITUTION: A method for determining an effect for type 2 diabetes comprises: a step of administering therapeutic agent candidate drug for type 2 diabetes to an experimental animal; a step of collecting urine; a step of measuring the concentration of metabolite related to blood glucose reduction; and a step of comparing with the concentration of control group. The metabolite is glucose, succinate, 2-oxoglutarate, or taurine.
Abstract translation: 目的：提供一种确定2型糖尿病影响的方法，以简单了解治疗性候选药物治疗2型糖尿病的治疗效果。 构成：确定2型糖尿病效果的方法，包括：向实验动物施用2型糖尿病候补药物的步骤; 收集尿液的一个步骤; 衡量与血糖降低相关的代谢物浓度的步骤; 并与对照组的浓度进行比较。 代谢物是葡萄糖，琥珀酸，2-氧戊二酸或牛磺酸。
-
10.发明授权
公开(公告)号：KR101540647B1
公开(公告)日：2015-08-05
申请号：KR1020130055866
申请日：2013-05-16
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본발명은약물유전형진단방법과약물반응예측방법에관한것으로, 보다상세하게는약물의효과, 이상반응예측, 약동학적반응관련된약물유전자들을조합하여, 많은약물유전형을대용량으로분석가능한최적의분석방법으로분석하고, 그유전형분석결과를이용하여개인의약물반응을예측하는방법에관한것이다. 같은약물이라도사람에따라약물반응이다르게나타나부작용이많이발생하거나, 약효가나타나지않는다. 그러나본 발명을이용하여약물을복용하기전 개인의약물유전형을진단하고약물반응을미리예측하면, 본인에적합한약물의종류, 적정용량을사용할수 있게된다. 본발명으로인하여약물로인한부작용은최소화하고, 약효는최대화하는개인맞춤약물요법을실현할수 있다.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.025 seconds)
